Atogepant

Summary

Atogepant (CHEMBL3991065) is an approved small-molecule calcitonin gene-related peptide receptor antagonist (ATC N02CD07); indicated across 1 condition including migraine disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02CD07
• Indications: 1 condition
• Clinical trials: 26
• Chemistry: 603.5 Da · C29H23F6N5O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3991065
Name	Atogepant
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	72163100
ChEBI	CHEBI:196955
ATC	N02CD07
Molecular formula	C29H23F6N5O3
Molecular weight	603.5
InChIKey	QIVUCLWGARAQIO-OLIXTKCUSA-N

SMILES: C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F

IUPAC name: (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-carboxamide

ChEBI definition: A secondary carboxamide resulting from the formal condensation of the carboxy group of (3’S)-2’-oxo-1’,2’,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3’-pyrrolo[2,3-b]pyridine]-3-carboxylic acid with the amino group of (3S,5S,6R)-3-amino-6-methyl-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-2-one. It is a selective oral, small-molecule antagonist of calcitonin gene-related peptide (CGRP) receptor that has been approved for the treatment of migraine.

Pharmacological roles (ChEBI): calcitonin gene-related peptide receptor antagonist.

Also known as: AGN-241689, Aquipta, Atogepant, MK-8031, Qulipta, ATOGEPANT

Parent form; salt/anhydrous children: CHEMBL3981883

Patent coverage: 106 distinct patent families (251 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 183 (73%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	CGRP receptor	Antagonist	10.82

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Calcitonin-gene-related peptide receptor, CALCRL/RAMP1, Calcitonin gene-related peptide type 1 receptor.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
RAMP1	10.82	Ki	0.01	nM	CHEMBL_ACT_20657861
CALCRL	10.82	Ki	0.01	nM	CHEMBL_ACT_27425645
CALCRL	10.82	Ki	0.01	nM	CHEMBL_ACT_27562400

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
migraine disorder	4	MONDO:0005277	MONDO:0005277

Clinical trials

Total trials: 26.

Phase distribution

Phase	Trials
PHASE3	16
Not specified	5
PHASE4	2
PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06972056	PHASE4	RECRUITING	Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT05264129	PHASE4	COMPLETED	Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
NCT05707949	PHASE3	ENROLLING_BY_INVITATION	Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05711394	PHASE3	RECRUITING	A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05748483	PHASE3	ACTIVE_NOT_RECRUITING	Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT06241313	PHASE3	ACTIVE_NOT_RECRUITING	Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06806293	PHASE3	ACTIVE_NOT_RECRUITING	Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06810505	PHASE3	RECRUITING	A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT02848326	PHASE2/PHASE3	COMPLETED	Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
NCT03700320	PHASE3	COMPLETED	Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
NCT03777059	PHASE3	COMPLETED	12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
NCT03855137	PHASE3	COMPLETED	Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
NCT03939312	PHASE3	COMPLETED	Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
NCT04437433	PHASE3	COMPLETED	A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
NCT04686136	PHASE3	COMPLETED	A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04740827	PHASE3	COMPLETED	Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
NCT04829747	PHASE3	COMPLETED	Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine
NCT05216263	PHASE3	COMPLETED	Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
NCT05861427	PHASE3	COMPLETED	Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
NCT04818515	PHASE1	COMPLETED	Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine
NCT05892757	PHASE1	COMPLETED	Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
NCT06212661	Not specified	ENROLLING_BY_INVITATION	Migraine Medication Effects on Urinary Symptoms
NCT06414044	Not specified	ACTIVE_NOT_RECRUITING	Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
NCT06603558	Not specified	RECRUITING	Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
NCT06882122	Not specified	RECRUITING	Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
NCT06136442	Not specified	UNKNOWN	Atogepant in Real Life in Italy (GIANT)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).